Friday, April 23, 2021
Zydus Cadila(Pharma company) today (23rd April 2021) received restricted Emergency use approval from India’s drug regulator for the use of Virafin, Pegylated Interferon alpha-2b (PegIFN) in treating moderate Covid-19 infection in adults.
When administered early on during Covid, Virafin will help patients recover faster and avoid much of the complications, the company said in a statement.
Virafin will be available on the prescription of a medical specialist for use in a hospital setup.
“A single dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients,” the company said.
In its Phase III clinical trials, the therapy had shown better clinical improvement in the patients suffering from Covid-19. "The drug ensures faster viral clearance and has several add-on advantages compared to other anti-viral agents”.
